Hepatocellular carcinoma (HCC) is one of the most deadly cancers worldwide. It is well known that the activation of PI3K/AKT/mTOR and the Ras/MAPK signaling pathway plays a critical role in cellular metabolism, growth and proliferation, and its inhibitors have been used as therapeutic drugs for hepatocellular carcinoma. Cetuximab, a chimerical monoclonal EGFR IgG1 antibody, can block the binding of EGF or other ligands to EGFR and thus inhibit ligands-induced receptor phosphorylation. In the present study, we found that rapamycin could enhance the antiproliferation effect of cetuximab in both HepG2 cells and Huh-7 cells and arrest the cell cycle. Cetuximab in combination with rapamycin had synergistic effects on inhibiting the phosphrylation of proteins in PI3K/AKT/mTOR and Ras/MAPK signaling pathway. Combination of cetuximab with rapamycin treatment significantly suppressed the HCC development in HepG2 cells-xenografted mice and improved the survival. Cetuximab and rapamycin inhibited the growth of HCC both in vitro and in vivo. These results suggest that the combination therapy using the inhibitors for both EGFR and PI3K/AKT/mTOR signaling pathways may be a novel therapeutic approach for HCC.
Introduction
Hepatocellular carcinoma (HCC) is one of the most malignant and lethal cancers worldwide. Although HCC has been extensively studied, the therapeutic strategies remain unsatisfactory. Therefore, the innovative treatment approaches are urgently needed.
The epidermal growth factor receptor (EGFR) is a member of ErbB family of membrane-bound receptor tyrosine kinases (RTKs) that consist of four receptors including EGFR (ErbB-1), HER-2/neu (ErbB-2), HER-3 (ErbB-3), and HER-4 (ErbB-4). After binding with ligands, the EGFR is activated by homo-dimerization or hetero-dimerization, which leads to subsequent activation of EGFR tyrosine kinase (TK) activity and regulates receptor-mediated signal transduction, cell mitogenesis, and cell transformation (1) (2) (3) (4) (5) (6) (7) . EGFR signaling pathway contributes to a number of processes, including cell proliferation, apoptosis, angiogenesis, and metastatic spread. It plays a critical role in various cancers. EGFR is abnormal, enhanced and/or constitutively expressed in many types of tumors. Targeting EGFR signaling pathway with monoclonal antibodies or small molecule inhibitors has become a therapeutic option in many cancers. Inhibiting EGFR and its specific TK activity is regarded as a promising approach for innovative therapeutic strategies in cancer treatment (1) .
Several reports indicate that EGFRs are expressed frequently in human HCC, most likely contributing to the aggressive growth characteristics of these tumors (8) (9) (10) . EGFR overexpression in poorly differentiated HCCs (8-10) is a negative prognostic factor for tumor recurrence and extrahepatic metastasis (11, 12) , making it a promising therapeutic target for HCC treatment and other EGFR-overexpressed tumors. Hence, the EGFR can be a promising target for innovative treatment strategies in HCC.
A number of drugs such as erlotinib, gefitinib, and cetuximab (13, 14) have been developed, which block the EGFR signaling pathway at different points. Cetuximab is a chimerical monoclonal EGFR IgG1 antibody, specifically binds to EGFR with 5-to 10-fold higher affinity compare to endogenous ligands. Cetuximab blocks the binding of EGF or other ligands with EGFR and inhibits ligands-induced receptor phosphorylation (15, 16) . Several clinical studies demonstrated cetuximab's efficacy as a single agent or in combination with chemotherapeutic agents in hepatocellular cancer, refractory colorectal cancer, head and neck cancers, etc. (17) (18) (19) . Cetuximab can inhibit the growth of HepG2 cells in a time-dependent and dose-dependent manners (16) . Cetuximab exerts its antitumor activity through many important downstream signaling pathways such as PI3K/AKT/mTOR and Ras/MAPK signaling pathway, including apoptosis, cell cycle control, and angiogenesis (20, 21) . However, the antiproliferative effect of cetuximab is still controversial, recent clinical trials reported disappointed results in HCC patients (22) (23) (24) . These data revealed that some EGFR downstream pathways remain activated despite total EGFR is blocked. Thus, to improve the efficacy of EGFR inhibitors, it is necessary to combine EGFR inhibitors with downstream pathways inhibitors in treating different cancers such as HCC.
The mTOR is a downstream component of PI3K/AKT/ mTOR signaling pathway. The two major phosphorylation targets of mTOR are 40S ribosomal subunit p70 S6 kinase (p70S6K) and a translation repressor (4E-Bp1). Phosphorylation of p70S6K and 4E-Bp1 results in p70S6K activation but 4E-Bp1 inactivation (25) (26) (27) . Rapamycin can form the complex with immunophilin FK506-binding protein 12, leading to the specific inhibition of the serine/threonine protein kinase mTOR (3, 28) . Therefore, inhibition of the mTOR by rapamycin results in decreased translation of the RNAs that regulate cell cycle progression and proliferation, and thus leads to growth arrest and apoptosis (29) (30) (31) . Rapamycin has been recognized to disrupt the formation of cyclin/cyclindependent kinase/P21/proliferating cell nuclear antigen complexes by down-regulation of P21 (32) . Rapamycin can be used as a therapeutic drug itself or in combination with other chemotherapy drugs for treating various types of human malignant cancers including breast cancer (28, (33) (34) (35) (36) .
Since the PI3K/AKT/mTOR signaling pathway can be activated via a variety of receptor protein tyrosine kinases (RPTKs), inhibition of EGFR by cetuximab can only achieve a partial inhibition of this pathway. A combination of rapamycin and cetuximab is expected to block the PI3K/ AKT/mTOR and Ras/MAPK signaling more effectively. To our knowledge, however, there is no report regarding the preclinical or clinical study on the combined therapies for HCC using rapamycin and cetuximab. Therefore, the present study was to investigate the therapeutic efficacy of the combined therapy of rapamycin and cetuximab in HCC.
Materials and Methods

Cell Lines and Culture Conditions
Human HCC cell lines (HepG2 and Huh-7) were obtained from ATCC (American Type Culture Collection, Rockville, MD) and cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum (FBS), 4 mM/l glutamine, 50 U/ml penicillin, and 50 mg/ml streptomycin. Cells were cultured at 378C in 5% CO 2 .
Cell Viability Assay
HepG2 cells and Huh-7 cells were plated in 96-well plate at a density of 1 3 10 4 cells/well. After 24 h culture, the cells were treated with cetuximab at the following dosages: 0.04, 0.08, 0.16, 0.32, 0.64, 1.25, 2.5, 5, and 10 µg/ml, or rapamycin at the following dosages: 0, 4, 8, 16, 32, 64, 125, 250, 500, and 1000 nM, or the combination of 10 µg/ml cetuximab and different dosages of rapamycin (0, 4, 8, 16, 32, 64, 125, 250, 500, and 1000 nM) for 48 h. 20 µl of MTT (Sigma, St. Lous, MO) solution (5 mg/ml) were added to each well. Cells were incubated at 378C for 4 h. The supernatant of each well was carefully removed, then 150 µl DMSO were added to each well and mixed thoroughly on a shaker for 10 min. The absorbance at 595 nm was detected by a DNA microplate reader.
Cell Cycle Analysis
HepG2 cells were plated at a density of 1 3 10 5 cells/well in six-well plate overnight. The cells were treated with 10 µg/ml cetuximab or 200 nM rapamycin or the combination of cetuximab (10 µg/ml) and rapamycin (50, 100 or 200 nM) for 24 h. The cells were harvested by gentle trypsinization, centrifuged at 1500 g for 5 min, washed once in ice-cold PBS, and followed by fixation in 75% ethanol overnight at 2208C. The cells were stained with 50 µg/ml PI in the presence of 100 µg/ml RNase A for 30 min at 378C in the dark. Quantification of the cell cycle distribution was done by flow cytometric analysis.
Western Blotting
Hepatoma cell lines were plated in six-well plate (1 3 10 5 cells/well) as described above, and treated with the cetuximab or rapamycin or the combination of both drugs at variable concentrations for 48 h. The cells were washed with ice-cold PBS and harvested in 100 µl of M2 lysis buffer (20 mM Tris (pH 7.0), 1% Triton-X 100, 0.5% NP-40, 250 mM NaCl, 3 mM EDTA, 3 mM EGTA, and 2 mM DTT) containing protease inhibitors (Sigma). Cell lysate was obtained by 13000Xg centrifugation for 15 min at 48C and protein concentration was determined by the bicinchoninic acid (BCA) method (Pierce, Rockford, IL). Cell lysates (40 µg/lane) were separated on 12% SDS-PAGE and transferred onto a polyvinylidenedifluoride (PVDF) membrane (Millipore, Billerica, MA). The membrane was blocked with 5% bovine serum albumin (BSA) in TBST (Tris-buffered saline with 0.1% Tween 20) for 1 h and then incubated overnight at 48C with anti-EGFR, anti-phospho-Akt, anti-Akt, anti-phospho-Erk, anti-Erk, anti-phospho-P70S6K or anti-P70S6K antibodies (Cell Signaling Technology, Danvers, MA). After three washes in TBST, the membrane was incubated with the appropriate secondary antibodies conjugated with HRP for 1 h at room temperature. The immunoreactive bands were developed using ECL reagent (Pierce) and visualized using autoradiography on X-ray film (Kodak, Rochester, NY). Relative protein expression was normalized to GAPDH intensity.
Xenograft Model of HCC
Female nu/nu BALB/c mice (4-6 weeks old) were obtained from Vitral River Laboratories (Beijing, China). The mice were fed with sterilized food and water and housed in barrier environment with 12:12 h light-dark cycle. 2 3 10 6 HepG2 cells were injected subcutaneously into the fat pad of nude mice and allowed xenograft to grow for 7 days. Mice were randomly divided into four groups, six mice in each group (n 5 6). The control group was intravenously (IV) injected with 5 mg/kg IgG weekly. The other three groups were IV administered with 5 mg/kg cetuximab, 1 mg/kg rapamycin, and the combination of cetuximab and rapamycin weekly, respectively. The mice were observed once a week for the tumor volume and survival rate. Tumor volume was calculated using the following formula: a 2 3 b 3 0.5, where a is the smaller dimension and b is the larger dimension of the tumor. The mice in this study were used and treated following the international guidelines for the care and use of laboratory animals, and approved by Animal Ethics Committee of Institute of Basic Medical Sciences.
Results
Growth Inhibitory Effects of Cetuximab or Rapamycin on HCC cells
Growth inhibition by cetuximab or rapamycin on HepG2 and Huh-7 hepatoma cells was studied by measuring cell proliferation. Compare to untreated controls, cetuximab inhibited the proliferation of HepG2 cells by up to 30% in a dose-dependent manner ( Figure 1A) , while rapamycin dose-dependently inhibited HepG2 cells proliferation by up to 36% ( Figure 1B) . Moreover, the combination of cetuximab (10 µg/ml) and increasing rapamycin (0-1000 nM/ml) led to dramatical cell growth inhibition in a dose-dependent manner, in which the inhibitory effects were much stronger than that of cetuximab or rapamycin treatment alone (p , 0.02 and p , 0.05 separately, Figure 1C ). However, Huh-7 cells was less sensitive to cetuximab treatment and more sensitive to rapamycin treatment when compared with HepG2 cells. Cetuximab in inhibited the proliferation of Huh-7 cells by up to 20% in a dose-dependent manner ( Figure 1D ), while rapamycin dose-dependently inhibited Huh-7 cells proliferation by up to 50% ( Figure  1E ). Combination treatment with cetuximab and increasing rapamcin inhibited the proliferation of Huh-7 cells in a dose-dependent manner and more significant than treatment with cetuximab and rapamycin alone (p , 0.02 and p , 0.05 separately, Figure 1F ). Thus, rapamycin can enhance the antiproliferation effect of cetuximab in both HepG2 and Huh-7 cells.
Effects of Cetuximab and Rapamycin on Cell Cycle
Cell cycle analyses by flow cytometry were performed to test whether cetuximab and rapamycin can induce cell cycle arrest. After incubating HepG2 cells with 10 µg/ml cetuximab or 200 nM/ml rapamycin, the proportion of cells in the G0/G1-phase was increased while the proportion of cells in the S-phase was reduced ( Figure 2 ). After treatment with 10 µg/ml Cetuximab in combination with increasing rapamycin (50-200 nM/ml) for 24 h led to increasing arrest of the cells in the G0/G1-phase in a dose-dependent manner, accordingly, decreased the proportion of cells in the S-phase ( Figure 2) . These data suggest that cetuximab and rapamycin have synergistic effect on inhibiting cell cycle. 
Regulation of Cetuximab and Rapamycin in the Activation of PI3K/AKT/mTOR and Ras/MAPK Pathway
To characterize the effect of cetuximab in combination with rapamycin on EGFR signaling pathway, we examined the phosphorylation status of EGFR downstream proteins with or without EGF stimulation. We found that phosphorylation status of proteins in PI3K/AKT/mTOR and Ras/MAPK pathways were different in HepG2 cells and Huh-7 cells after treatment with cetuximab or rapamycin or cetuximab in combination with rapamycin. After cetuximab treatment, the phosphorylation of AKT and Erk was inhibited in both HepG2 cells and Huh-7 cells, but the blockade of EGFR by cetuximab did not affect the activation of P70S6K ( Figure 3A) . After rapamycin treatment, the phosphorylated P70S6K was reduced. Moreover, cetuximab and rapamycin had synergistic effect on inhibiting the phosphrylation of proteins in PI3K/AKT/mTOR and Ras/MAPK signaling pathway ( Figure 3B ).
The Synergistic Effect Cetuximab and Rapamycin on the Xenograph Tumor Growth of HepG2 Cells
The synergistic effect of cetuximab and rapamycin on in vivo antitumor growth was evaluated in xenograft nude mice model. The mice with xenograft tumor from HepG2 cells were randomly divided into four groups on day 11 of injection, and respectively treated with 5 mg/kg IgG (placebo control), 1 mg/kg cetuximab, 5 mg/kg rapamycin, or combined cetuximab and rapamycin weekly. The tumor size was measured weekly at and after treatment. Compared to placebo control, one week after treatment, the tumor volume in cetuximab and rapamycin groups respectively was reduced by 59% and 38%, while the tumor size was reduced by 82% after combined treatment with cetuximab and rapamycin ( Figure 4A) . These data suggest that the combined treatment of cetuximab and rapamycin has more effective therapeutic efficacy in HCC. 
Effects of Cetuximab and Rapamycin on the Survival of Xenograft Mice
The survival of xenograft nude mice was evaluated by a Kaplan-Meier curve ( Figure 4B ). The mice in IgG-treated group died on 12 or 13 days, while the survival of mice after rapamycin, cetuximab, and combined treatment of cetuximab and rapamycin was prolonged as long as 23, 29, and 27 days, respectively.
Discussion
HCC is a deadly form of cancer without effective chemotherapy so far worldwide. Although HCC has been extensively studied, the treatment efficacy of HCC is still unsatisfactory and the prognosis of patients suffering from advanced HCC is poor. Currently, only sorafenib, a multi-targeted tyrosine kinase inhibitor, has been verified to slightly improve the survival in HCC patients (37) . Thus the need for novel therapeutic approaches is urgent.
It is known that EGFR is overexpressed in various cancers. The EGF/EGFR signaling pathway is known to have strong stimulatory effect on the growth of hepatoma cells (38) . Several reports have demonstrated that EGFR overexpression is one of common features of HCC (9, 39) , hence targeting the EGFR signaling pathway is a rational and innovative treatment strategy in HCC.
Cetuximab, a specific EGFR monoclonal antibody, inhibits the growth of a variety of human cancer cells (11) , indicating the role of EGFR signaling pathway as a potential target for innovative treatment in HCC. However, cetuximab has not been tested for the treatment of HCC so far. In this study, we provided evidence that the combined therapy of cetuximab and rapamycin might be a promising anticancer strategy for HCC. Moreover, we showed that cetuximab caused the cytostatic effect in HCC. Many reports indicate EGFR blockade can lead to cell cycle arrest and/or apoptosis induction. The roles of EGFR inhibition in cell cycle arrest and/or apoptosis vary in different tumor types, but the exact mechanisms of cell cycle arrest and apoptosis by EGFR-inhibition are not known yet.
It has been found in recent studies that activation AKT/mTOR and Ras/MAPK pathway is frequently observed and associated with aggressive tumor phenotype and poor prognosis in human HCC (40) (41) (42) (43) (44) (45) . It has been demonstrated that the PI3K/ Akt/mTOR pathway plays an important role in cell growth, survival, differentiation, and metabolism (46) . Inhibition of PI3K/Akt/mTOR signaling pathway causes cell death associated with apoptosis and/or autophagy (47) . Moreover, the aberrant activation of PI3K/Akt/mTOR signaling pathway is implicated to have poor prognosis and has a critical role in the pathogenesis of HCC. The inhibition of this pathway decreases the lipogenesis activation and HCC hepatocarcinogenesis as well. Overexpression of AKT alone is sufficient to induce hepatocarcinogenesis in the mouse, suggesting that AKT de-regulation has a pivotal role in HCC (41) . Consistent with the pivotal role of Akt pathway in HCC pathogenesis, levels of activated AKT are almost ubiquitously up-regulated in human HCC (41) .
The Ras/MAPK pathway (also know as the RAF/MEK/ ERK pathway) is an ubiquitous signal and highly conserved pathway that involved in crucial cellular processes, including cell proliferation, differentiation, angiogenesis, invasion, and survival (48) . Importantly, the overexpression or activation of components of this pathway is believed to contribute to tumorigenesis, tumor progression and disease metastasis in a variety of solid tumors (49, 50) . The abnormal activation of the Ras/MAPK signaling pathway is associated with increased HCC tumor size (51) . Overexpression of MAPK (ERK1/2) was detected in 91% of HCCs and the phosphorylation of MAPK (ERK1/2) was detected in 69% of HCCs (52) . Overexpression of Ras proteins is frequently observed in HCC (40) . The activation of Ras/MAPK pathway play a positive role in HCC proliferation (53) .
Thus suppression of both AKT/mTOR and Ras/MAPK cascades might be helpful in treating HCC more effectively. Several studies have been made to target these pathways as therapy strategy. Villanueva et al. combination used a rapamycin analogue, everolimus, and an EGF/VEGF inhibitor, AEE788, to treated the Huh7 HCC cell line, which resulted in the inhibition of mTOR signaling in vitro and decreased tumor progression and increased survival in xenograft model (42) . Newell et al. used sorafenib and rapamycin to target mTOR and Ras/MAPK signaling. The combination of rapamycin and sorafenib decreased proliferation and induced apoptosis in HCC cell lines, and enhanced tumor necrosis and ucleration in a xenograft mouse model when compared with sorafenib alone (54) .
In an initial in vitro study, cetuximab inhibited cell growth, induced cell cycle arrest and moderately increased apoptosis in HepG2 cells (55) . However, it only had limited effects in Huh-7 cells. In our study, both cetuximab and rapamycin inhibited the growth of HepG2 and Huh-7 cells in a dose-dependent manner. Cetuximab only had limited effects in Huh-7 cells. Combination of cetuximab and rapamycin had stronger inhibitory effect on the growth of HepG2 cells and Huh-7 cells, meanwhile led to stronger arrest in the G1/G0-phase of cell cycle in HepG2 cells. HepG2 cells and Huh-7 cells treated with cetuximab inhibited the phosphorylation of AKT and ERK but not the activation of P70S6K, while the phosphorylation of P70S6K was inhibited by rapamycin treatment.
Although the EGF/EGFR activation leads to the activation of PI3K/AKT/mTOR pathway and Ras/MAPK pathway, EGFR blockade alone only decrease AKT and ERK activation but failed to decrease P70S6K activation in HepG2 and Huh-7 cell line. Thus, low-level EGFR activation or EGF signaling through other receptors continues to result in P70S6K activation. The addition of rapamycin to cetuximab completely blocked P70S6K phosphorylation in/without the presence of EGF. We hypothesize that the inhibition of PI3K/AKT/mTOR and Ras/ MAPK pathways will provide superior antiproliferative efficacy compare to the blockade of single pathway. Nevertheless, we have proven the concept that targeting multiple pathways with small molecules may be a good therapeutic strategy, and in particular combined blockade of EGFR and mTOR pathways may improve the therapeutic efficacy of EGFR inhibitors.
Our studies indicated that the combined use of cetuximab and rapamycin could inhibit the development of HCC xenografts in mice and improve the survival. We demonstrated the cell growth inhibitory effect of cetuximab and rapamycin on HCC cells both in vitro and in vivo, and explored the possible mechanism. Therefore, the combined treatment of cetuximab and rapamycin may be a novel therapeutic strategy for HCC.
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